Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ustekinumab biosimilar QX001S
- Development stage
- Unknown
- Lead developer
- Qyuns Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
QX001S is a biosimilar of ustekinumab, developed by Qyuns Therapeutics and Zhongmei Huadong. It is the first approved ustekinumab biosimilar in China. Ustekinumab is a monoclonal antibody that targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), preventing their interaction with the IL-12Rβ1 receptor on immune cells. This inhibition blocks downstream signaling and cytokine cascades mediated by IL-12 and IL-23, which are key drivers in immune-mediated inflammatory diseases such as psoriasis and Crohn’s disease. QX001S has demonstrated pharmacokinetic equivalence to reference ustekinumab, with similar safety and immunogenicity profiles[1][2][3][4][5].
- Brand names
- SAILEXIN
- Other names
- ustekinumab injectionStelara
02
Targets
IL-23 (Interleukin-23)
Beyond the preview
Go deeper on ustekinumab biosimilar QX001S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ustekinumab biosimilar QX001S.